Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Quanterix
(NASDAQ:QTRX)
Intraday
$14.00
-1.59
[-10.20%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$14.00
-1.59
[-10.20%]
Last update: 5:59PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Quanterix Stock (NASDAQ:QTRX)
Quanterix Stock (NASDAQ: QTRX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, March 21, 2024
Quanterix Reveals Specific Partnership Path For Laboratories Interested In Offering Tau Based Research And Diagnostic Testing Services
Benzinga Newsdesk
-
Mar 21, 2024, 5:32PM
Monday, March 04, 2024
Scotiabank Maintains Sector Outperform on Quanterix, Raises Price Target to $32
Benzinga Newsdesk
-
Mar 4, 2024, 11:21AM
Quanterix Granted Breakthrough Device Designation From U.S. FDA For Blood-Based p-Tau 217 Test For Alzheimer's Disease
Benzinga Newsdesk
-
Mar 4, 2024, 9:02AM
Thursday, February 29, 2024
Quanterix Sees FY24 Revenue $139M-$144M Vs $138.2M Est.
Benzinga Newsdesk
-
Feb 29, 2024, 4:16PM
Quanterix Q4 EPS $(0.33) Misses $(0.32) Estimate, Sales $31.55M Beat $29.84M Estimate
Happy Mohamed
-
Feb 29, 2024, 4:15PM
Earnings Scheduled For February 29, 2024
Benzinga Insights
-
Feb 29, 2024, 5:15AM
Wednesday, February 28, 2024
Earnings Preview: Quanterix
Benzinga Insights
-
Feb 28, 2024, 12:02PM
Tuesday, February 27, 2024
Earnings Scheduled For February 27, 2024
Benzinga Insights
-
Feb 27, 2024, 5:01AM
Reported Earlier, Quanterix Reaffirmed Its 2023 Guidance, Expects GAAP Gross Margin In The High 50s Percent, And Non-GAAP Gross Margin To Be Around 50%; Q4 Earnings Call Rescheduled
Benzinga Newsdesk
-
Feb 27, 2024, 3:10AM
Monday, February 26, 2024
A Preview Of Quanterix's Earnings
Benzinga Insights
-
Feb 26, 2024, 3:01PM
Quanterix Announces First Collaborations With Five Health Networks To Aid The Diagnosis And Clinical Management Of Individuals With Alzheimer's Disease
Benzinga Newsdesk
-
Feb 26, 2024, 9:02AM
Earnings Scheduled For February 26, 2024
Benzinga Insights
-
Feb 26, 2024, 4:47AM
Friday, February 23, 2024
Earnings Outlook For Quanterix
Benzinga Insights
-
Feb 23, 2024, 1:01PM
Monday, November 06, 2023
Quanterix Q3 EPS $(0.21) Beats $(0.37) Estimate, Sales $31.33M Beat $27.59M Estimate
Benzinga Newsdesk
-
Nov 6, 2023, 5:30PM
Earnings Scheduled For November 6, 2023
Benzinga Insights
-
Nov 6, 2023, 8:24AM
Friday, November 03, 2023
A Preview Of Quanterix's Earnings
Benzinga Insights
-
Nov 3, 2023, 2:01PM
Tuesday, October 24, 2023
Quanterix shares are trading higher after the company announced a new agreement with Janssen Sciences Ireland UC to advance blood based Alzheimer's Disease detection.
Benzinga Newsdesk
-
Oct 24, 2023, 11:19AM
Monday, October 23, 2023
Quanterix Announces New Agreement With Janssen Sciences Ireland UC, To Advance Blood Based Alzheimer's Disease Detection
Benzinga Newsdesk
-
Oct 23, 2023, 10:17PM
Thursday, September 28, 2023
Analyst Expectations for Quanterix's Future
Benzinga Insights
-
Sep 28, 2023, 11:00AM
Goldman Sachs Maintains Buy on Quanterix, Raises Price Target to $34
Benzinga Newsdesk
-
Sep 28, 2023, 8:33AM
Wednesday, September 27, 2023
Goldman Sachs Maintains Buy on Quanterix, Raises Price Target to $34
Benzinga Newsdesk
-
Sep 27, 2023, 8:15AM
Monday, September 25, 2023
Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023
Benzinga Insights
-
Sep 25, 2023, 11:00AM
Canaccord Genuity Upgrades Quanterix to Buy, Raises Price Target to $32
Benzinga Newsdesk
-
Sep 25, 2023, 9:13AM
Wednesday, August 09, 2023
Goldman Sachs Maintains Buy on Quanterix, Raises Price Target to $30
Benzinga Newsdesk
-
Aug 9, 2023, 11:54AM
Quanterix Appoints Vandana Sriram As Chief Financial Officer, Effective August 21, 2023
Benzinga Newsdesk
-
Aug 9, 2023, 8:39AM
Tuesday, August 08, 2023
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
Aug 8, 2023, 1:13PM
Quanterix shares are trading higher after the company reported better-than-expected Q2 financial results.
Benzinga Newsdesk
-
Aug 8, 2023, 12:06PM
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday
Lisa Levin
-
Aug 8, 2023, 10:35AM
Monday, August 07, 2023
Quanterix Q2 EPS $(0.16) Beats $(0.38) Estimate, Sales $31.03M Beat $25.92M Estimate
Benzinga Newsdesk
-
Aug 7, 2023, 5:16PM
Monday, July 31, 2023
Quanterix Corporation shares are trading higher after the company announced its Simoa technology supported a large international study to establish sNfL reference ranges to assess neurological disease activity in children and adolescents.
Benzinga Newsdesk
-
Jul 31, 2023, 1:25PM
Quanterix's Simoa Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light To Assess Neurological Disease Activity In Pediatric Patients
Benzinga Newsdesk
-
Jul 31, 2023, 8:03AM
Tuesday, July 25, 2023
'As Alzheimer's Drugs Hit The Market, The Race For Early Detection Blood Tests Heats Up' - Stat News
Happy Mohamed
-
Jul 25, 2023, 10:22AM
Friday, July 07, 2023
Quanterix shares are trading higher after the company announced it launched LucentAD test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer's disease.
Benzinga Newsdesk
-
Jul 7, 2023, 10:43AM
Thursday, July 06, 2023
Quanterix Launches LucentAD Test To Assist In Evaluation Of Patients Experiencing Cognitive Symptoms Consistent With The Early Signs Of Alzheimer's Disease
Benzinga Newsdesk
-
Jul 6, 2023, 5:39PM
Wednesday, May 24, 2023
Goldman Sachs Maintains Buy on Quanterix, Raises Price Target to $27
Benzinga Newsdesk
-
May 24, 2023, 7:56AM
Tuesday, May 23, 2023
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
May 23, 2023, 1:46PM
Goldman Sachs Turns Bullish On Biotech With 'Significant Opportunity'
Priya Nigam
-
May 23, 2023, 12:03PM
Quanterix shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target from $13 to $27.
Benzinga Newsdesk
-
May 23, 2023, 11:24AM
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2023
Benzinga Insights
-
May 23, 2023, 11:00AM
Goldman Sachs Upgrades Quanterix to Buy, Raises Price Target to $27
Benzinga Newsdesk
-
May 23, 2023, 5:15AM
Tuesday, May 09, 2023
Recap: Quanterix Q1 Earnings
Benzinga Insights
-
May 9, 2023, 4:05PM
Quanterix Q1 EPS $(0.16) Beats $(0.38) Estimate, Sales $28.46M Beat $25.40M Estimate
Benzinga Newsdesk
-
May 9, 2023, 4:02PM
Earnings Scheduled For May 9, 2023
Benzinga Insights
-
May 9, 2023, 6:03AM
Tuesday, April 25, 2023
FDA Accelerated Approval Of Tofersen Highlights Importance Of Blood Neurofilament Light Chain As Surrogate Endpoint In Neurology Therapeutic Trials
Happy Mohamed
-
Apr 25, 2023, 11:56PM
Thursday, March 09, 2023
Quanterix's Return On Capital Employed Insights
Benzinga Insights
-
Mar 9, 2023, 9:47AM
Monday, March 06, 2023
Quanterix Q4 EPS $(0.50) Versus $(0.55) Last Year, Sales $25.82M Beat $25.78M Estimate
Benzinga Newsdesk
-
Mar 6, 2023, 8:11AM
Earnings Scheduled For March 6, 2023
Benzinga Insights
-
Mar 6, 2023, 4:52AM
Friday, March 03, 2023
Preview: Quanterix's Earnings
Benzinga Insights
-
Mar 3, 2023, 12:00PM
Monday, January 23, 2023
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Jan 23, 2023, 4:31PM
Monday, January 09, 2023
Quanterix Expands Laboratory Developed Test Menu With Launch Of Neurofilament Light Chain Test
Benzinga Newsdesk
-
Jan 9, 2023, 8:46AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch